ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anflu®

Its studies are mostly in Influenza, Human, led by Sinovac Biotech.

Furthest: phase 4, since Aug 28, 20261 company-led study, 1 open or runningNext primary completion: Feb 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech11 open or runningphase 4since Aug 28, 2026Aug 28, 2026Feb 2027phase 4 · NCT07832201

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 28, 2026First study: phase 4 study in Influenza, HumanFirst studyNCT07832201 · 150 planned · China

Ahead

  1. Feb 2027Primary completion: phase 4 study in Influenza, HumanNCT07832201

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07832201Influenza, Human · China4RecruitingFeb 2027150

How it is read

Names in the registry

  • “Anflu®”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.